PA
JAZZ icon

PSI Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

PSI Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$123 – 850
2024
Q4 		$123 Hold
1
– – ﹤0.01% 857
2024
Q3 		$111 Hold
1
– – ﹤0.01% 860
2024
Q2 		$107 Hold
1
– – ﹤0.01% 840
2024
Q1 		$120 Hold
1
– – ﹤0.01% 778
2023
Q4 		$123 Hold
1
– – ﹤0.01% 841
2023
Q3 		$129 Hold
1
– – ﹤0.01% 824
2023
Q2 		$124 Hold
1
– – ﹤0.01% 814
2023
Q1 		$146 Hold
1
– – ﹤0.01% 756
2022
Q4 		$159 Hold
1
– – ﹤0.01% 734
2022
Q3 		$0 Buy
+1
New +$152 ﹤0.01% 801
2022
Q2 		– Sell
-1
Closed – – 809
2022
Q1 		$0 Hold
1
– – ﹤0.01% 761
2021
Q4 		$0 Hold
1
– – ﹤0.01% 790
2021
Q3 		$0 Buy
+1
New +$151 ﹤0.01% 723

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

PSI Advisors's JAZZ Position: Q1 2025 in Review

PSI Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 1 share — an estimated $123 sold.

PSI Advisors first reported a position in JAZZ in Q3 2021 and held it in 13 quarters. The position peaked at $159 in Q4 2022. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • PSI Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • PSI Advisors sold 1 Jazz Pharmaceuticals share in Q1 2025, an estimated $123.
  • PSI Advisors first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 13 quarters.
  • PSI Advisors's Jazz Pharmaceuticals position peaked at $159 in Q4 2022.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on PSI Advisors's 13F filing for Q1 2025, filed 21 Apr 2025.